PHARMACEUTICALS
“ The beauty of it is that when we combine both portfolios of generic APIs there is no overlap ,” Clavel says . “ It is a fully complementary portfolio of products and hence the combination creates a leader in generic APIs with a unique offering .” The product list now extends to 100 , with a broad range of customers and therapeutic indications . The offer , Clavel adds , is unique in that it is very diverse , with both large- and small-volume products , from > 100 tonnes / year to < 1 . While Seqens is still dwarfed by some of the giants of generics but it is not far behind other players like EuroAPI . “ Beyond the products , we also complete our manufacturing site footprint , specifically with the cGMP capabilities we now have in Israel , and we have enhanced our existing industrial expertise , such as in HPAPIs but even more so in particle engineering , with technologies like micronisation and spray drying , which we did not have before the acquisition .”
Option in insource
Previously , when capabilities like this were required for a customer project , Seqens had to outsource them . Now , the option is there to carry them out in-house as well . Indeed , it is already working on developing its own micronised versions of certain products . “ From Day One of the merger , we agreed we wanted to speak with one voice and combine our efforts . We organised a gathering to understand each other ’ s capabilities and the work to be share between teams . We started to work on synergies as soon as it was possible ,” Clavel says . In March , Seqens announced a multi-million investment in its R & D laboratory at Devens , Massachusetts , for completion end 2022 or beginning 2023 . A relocation is taking place from one site to another to increase the space available . This is aimed at ensuring that the new facility will operate at the highest standards of safety and quality , while
23